Navigation Links
Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
Date:6/5/2010

PARIS, June 5, 2010 /PRNewswire-FirstCall/ --

- One-Year Phase II Data Presented at the 2010 ACTRIMS Meeting

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.

The findings were the subject of the leading oral presentation at the American Committee for Treatment and Research in Multiple Sclerosis meeting (ACTRIMS) in San Antonio, TX, USA. This study is part of a comprehensive clinical development program for teriflunomide both in monotherapy and in adjunct therapy in MS patients.

Although this Phase II study (n=116) was not powered to test for efficacy, patients taking 7mg or 14mg teriflunomide in adjunct to stable dose IFN-[BETA] experienced a significant relative risk reduction (86%; p=0.0005 and 82.8%; p<0.0001 respectively) in the number of gadolinium enhancing T1 (T1-Gd) lesions on brain magnetic resonance imaging compared with patients taking stable dose IFN-[BETA] with placebo. No unexpected safety findings have been showed with teriflunomide during the one-year period of the study as compared to the initial six-month period. Discontinuations due to treatment-emergent adverse e
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder
2. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
3. Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer
4. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
5. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
6. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
7. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
8. Web Resource for Interferon Research
9. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
10. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
11. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Biochips ... to their offering. This report is ... and applications. The report starts with a description ... markets. Technologies include array comparative genomic hybridization (CGH), ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. This ... as a characteristic that can be objectively measured ... or pathogenic processes as well as pharmacological responses ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/bvxxkf/cytogenetics ) has announced the addition ... - Technologies, Markets and Companies" to ... cytogenetics includes several technologies besides fluorescence in ... and multicolor FISH. Molecular cytogenetics includes application ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... of botanical and plant-derived compounds. BCC Research reveals in its new report ... because this market defines the category and generates the most market demand. ...
Breaking Biology Technology:Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3
... -- Researchers in the Materials Science and Technology ... demonstrated electrical injection, detection and precession of spin ... device technology, at temperatures up to 225 degrees ... spin accumulation in Si is viable as a ...
... DRRX ) announced today financial results for the ... $8.6 million for the three months ended March 31, 2011 ... 2010.  Net loss for the three months ended March 31, ... $6.6 million for the same period in 2010.(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ...
... 5, 2011 PharmacoFore, Inc., a privately held biopharmaceutical ... it is a sponsor of the 2011 CLAAD National ... November 29, 2011 in Washington, DC. ... Inc., stated, "PharmacoFore shares CLAAD,s objective to prevent the ...
Cached Biology Technology:NRL scientists achieve high temperature milestone in silicon spintronics 2NRL scientists achieve high temperature milestone in silicon spintronics 3DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs 2DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs 3DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs 4DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs 5DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs 6DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs 7PharmacoFore, Inc. Announces Sponsorship of the 2011 CLAAD National Prescription Drug Abuse Prevention Policy Consensus Meeting on November 29, 2011 in Washington, DC 2PharmacoFore, Inc. Announces Sponsorship of the 2011 CLAAD National Prescription Drug Abuse Prevention Policy Consensus Meeting on November 29, 2011 in Washington, DC 3
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/12/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is proud to announce that iMedNet ... technology platform, has led the way to significant and ... 2015.   Q2 2015 and Q1 2015 were, respectively, ... value sold in the company,s 15 year history.  In ...
(Date:8/10/2015)... and TELTOW, Germany , August 10, ... (SMI), a world leader in Eye Tracking Technology for ... its OEM Eye Tracking Platform for integration into all ... contains reference designs for seamless integration of eye tracking ... reality HMDs and augmented reality smart glasses. Omnivision,s leading ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... new, interactive tool that will change the way medical education ... bright, promising medical student who died in a car crash, ... interfaces to help students learn anatomy and physiology in 3D. ... students see in real life - the LINDSAY software connects ...
... Researchers at Rice University and Lockheed Martin reported this ... high-performance anodes from a single silicon wafer. The process ... in rechargeable lithium-ion batteries, laying the groundwork for longer-lasting, ... and electric vehicles. The work led by Sibani ...
... comes to rodent robberswhich turns out to be a good ... their seeds. Results of a yearlong study in Panama, ... Sciences the week of July 16, suggest that thieving ... the seed-spreading role of the mighty mastodon and other extinct ...
Cached Biology News:LINDSAY: The future of medical education 2Toughened silicon sponges may make tenacious batteries 2Rodent robbers good for tropical trees 2
...
Human Cystatin A MAb (Clone 224705)...
Corticoliberin...
Anti-SDF-1β/PBSF affinity isolated antibody lyophilized powder Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline recombinant human SDF-1β/PBSF expressed in E....
Biology Products: